Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | recruiting | Phase 2 | 15 | University of RochesterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06668792 | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma(FLAMMINGO) | recruiting | Phase 2 | 100 | BiocadINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | recruiting | Phase 2 | 100 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06701357 | CR-CHOP+X in Previously Untreated DEL | recruiting | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06737250 | NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL(POTENTIAL-P) | recruiting | Phase 2 | 33 | NOBO MedicineINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06735495 | CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors | recruiting | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06083207 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 116 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT05665140 | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients(ELIAS) | recruiting | Phase 2 / Phase 3 | 100 | University Hopsital Schleswig Holstein Campus LübeckOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06698484 | To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)(CAR-T for NHL) | recruiting | Phase 2 | 20 | National University of MalaysiaOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06566586 | A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma | recruiting | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06393985 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma(V-MIND) | recruiting | Phase 2 | 100 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06674096 | RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL | recruiting | Phase 2 | 44 | Zhejiang Cancer HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05348213 | Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma(R-ICE+X) | recruiting | Phase 2 | 76 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06589089 | Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy | recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06647940 | Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial) | recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04070040 | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | recruiting | Phase 2 | 21 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | recruiting | Phase 1 / Phase 2 | 5 | Kara Yakhteh Tajhiz Azma CompanyNETWORK | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06418477 | Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD | recruiting | Phase 2 | 20 | Peking University People's HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | recruiting | Phase 2 | 120 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 5 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia(BBClean) | recruiting | Phase 2 / Phase 3 | 90 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06503263 | Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL | recruiting | Phase 2 | 240 | Navy General Hospital, BeijingOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06341556 | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT06553352 | Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma | recruiting | Phase 2 | 39 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06569485 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients | recruiting | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566807 | Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Huai'an First People's HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06554626 | Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL | recruiting | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | recruiting | Phase 2 | 39 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06430736 | PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)(PRONTO) | recruiting | Phase 2 | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06482684 | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma(CARMAN) | recruiting | Phase 2 | 150 | Christian Schmidt, MDOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06454968 | Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. | recruiting | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06461182 | Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma(PentixaFor) | recruiting | Phase 2 | 15 | Koo Foundation Sun Yat-Sen Cancer CenterOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05248633 | Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma | recruiting | Phase 2 | 220 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2025source: clinicaltrials